Form 4: Zomedica SVP Boosts Stake with $0.04 Stock Purchases

Zomedica Corp.'s Senior Vice President of Sales, Russell Kevin Klass, significantly increased his direct ownership of common stock through multiple purchases at $0.04 per share in August 2025.

Summary

• Russell Kevin Klass, Senior Vice President of Sales at Zomedica Corp., purchased common stock on two separate dates in August 2025.
• On August 11, 2025, Klass acquired 60,723 shares of common stock at a price of $0.04 per share.
• On August 12, 2025, Klass made two additional purchases: 250,000 shares and 745,341 shares, both at $0.04 per share.
• Following these transactions, Klass's direct beneficial ownership of Zomedica common stock increased to a total of 5,256,094 shares.

Sentiment

Score: 8

Explanation: The significant increase in direct beneficial ownership by a key executive signals strong internal confidence in the company's valuation and future prospects.

Positives

• Senior Vice President of Sales, Russell Kevin Klass, increased his direct beneficial ownership in Zomedica Corp. by purchasing a total of 1,056,064 shares.
• The purchases demonstrate management's confidence in the company's future prospects, as an insider is investing personal capital into the stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential positive signal due to insider confidence, which may lead to increased investor interest and potentially a positive impact on share price.
• Employees: May boost morale and confidence within the company if management is investing personal capital into the stock.

Key Dates

Recommendation

The substantial purchases of common stock by a Senior Vice President at Zomedica Corp. indicate strong insider confidence in the company's future performance and valuation, suggesting the stock may be undervalued at its current price of $0.04 per share.

Keywords

Zomedica, ZOMDF, insider trading, stock purchase, beneficial ownership, Form 4, Russell Kevin Klass, common stock